4/A: 180 Life Sciences Corp. Amends Executive Compensation Filing for Chief Accounting Officer

180 Life Sciences Corp. filed an amended Form 4 to reflect a retroactive adjustment to equity awards granted to Chief Accounting Officer Eric R. Van Lent, including restricted stock and stock options.

Summary

• Eric R. Van Lent, Chief Accounting Officer of 180 Life Sciences Corp., was granted 8,174 restricted common stock shares and 25,000 non-qualified stock options.
• The restricted stock shares vest in two equal tranches on December 17, 2025, and June 17, 2026, contingent on continued service to the Issuer.
• The stock options have an exercise price of $0.929 and vest in two equal tranches on December 17, 2025, and June 17, 2026, also contingent on continued service.
• The options expire on June 17, 2035.
• Both awards were granted as consideration for services rendered and agreed to be rendered to the Issuer.
• The 25,000 stock options are subject to stockholder approval of the 2025 Option Incentive Plan; they cannot be exercised until approval is obtained and will be cancelled if approval is not granted.
• This Form 4/A was filed to reflect a retroactive adjustment made by the Board of Directors and Compensation Committee on June 28, 2025, to ensure the awards complied with the 2022 Equity Compensation Plan.

Sentiment

Score: 6

Explanation: The grant of equity awards to a key executive is generally positive for aligning interests and retention. However, the contingency of the options on future stockholder approval and the need for a retroactive adjustment introduce minor uncertainties and suggest potential administrative issues.

Positives

• Granting of equity awards to the Chief Accounting Officer aligns management incentives with shareholder interests.
• The awards are subject to time-based vesting, encouraging long-term service and retention of key personnel.

Negatives

• The 25,000 stock options are contingent on future stockholder approval of the 2025 Option Incentive Plan, introducing uncertainty regarding their ultimate validity.
• The need for a retroactive adjustment suggests potential administrative oversight or planning issues regarding the equity plan capacity.

Risks

• The 25,000 stock options granted to the Chief Accounting Officer are subject to stockholder approval of the 2025 Option Incentive Plan; if approval is not obtained, these options will be cancelled.
• The vesting of both restricted stock and options is contingent on the recipient's continued service to the Issuer, meaning the awards could be forfeited if employment ceases.

Future Outlook

The validity of the 25,000 stock options is contingent on future stockholder approval of the 2025 Option Incentive Plan, which is a forward-looking event.

Management Comments

• This Form 4/A is being filed to reflect the fact that the number of shares awarded to the Reporting Person was retroactively adjusted by the Board of Directors and Compensation Committee of the Company on June 28, 2025, so that there was sufficient room for such award, and other awards made on the same date, under the Equity Plan.

Industry Context

This filing is a standard disclosure of executive compensation, common across publicly traded companies, reflecting the use of equity awards to incentivize and retain key management personnel. The specific details of the equity plan and the need for retroactive adjustment are company-specific rather than broad industry trends.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the Chief Accounting Officer's interests with shareholders, potentially improving long-term performance. However, the contingency of options on stockholder approval means shareholders will have a direct say on a portion of this compensation. The retroactive adjustment indicates a need for careful oversight of equity plan limits.
• Employees: The vesting schedule encourages retention of a key executive.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan is required for the 25,000 stock options to become exercisable.
• The restricted stock and options will vest in tranches on December 17, 2025, and June 17, 2026, subject to continued service.

Key Dates

Keywords

180 Life Sciences Corp., ATNF, SEC Form 4/A, Beneficial Ownership, Executive Compensation, Restricted Stock, Stock Options, Equity Compensation Plan, Chief Accounting Officer, Eric R. Van Lent, Corporate Governance, Insider Trading